Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H30N4O |
Molecular Weight | 426.5533 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=CC=CC=C2N1CCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
InChI
InChIKey=BAINIUMDFURPJM-UHFFFAOYSA-N
InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/24474428Curator's Comment: description was created based on several sources, including, http://www.hindawi.com/journals/jphar/2013/629593/
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24474428
Curator's Comment: description was created based on several sources, including, http://www.hindawi.com/journals/jphar/2013/629593/
Oxatomide is a H1-histamine receptor antagonist developed for the treatment of broad spectrum of allergic and other hypersensitivity reactions. The drug is currently marketed in Japan, Taiwan, Italy, Portugal, Indonesia, Argentina, South Africa.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18446005
Curator's Comment: May have sedative effect due to interaction with histamine receptor.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/8753840 |
6.23 null [pIC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TINSET Approved UsePrevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date1.41073921E12 |
|||
Primary | TINSET Approved UsePrevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date1.41073921E12 |
|||
Palliative | TINSET Approved UsePrevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date1.41073921E12 |
|||
Primary | TINSET Approved UsePrevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date1.41073921E12 |
|||
Primary | TINSET Approved UsePrevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date1.41073921E12 |
|||
Primary | TINSET Approved UsePrevention and treatment of allergic diseases: rhinitis, extrinsic asthma (excluding asthma attacks), follicular conjunctivitis, chronic urticaria, atopic dermatitis, food allergies. Launch Date1.41073921E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects. | 1995 Feb |
|
Effect of oxatomide, an antiallergic agent, on QT interval in dogs. | 2001 |
|
The role of central histaminergic neuron system as an anticonvulsive mechanism in developing brain. | 2001 Nov |
|
The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. | 2002 Dec |
|
Gateways to clinical trials. | 2002 Jan-Feb |
|
Oxatomide for stable asthma in adults and children. | 2003 |
|
Pranlukast: a review of its use in the management of asthma. | 2003 |
|
Enhancement of allergic skin wheal responses in patients with atopic eczema/dermatitis syndrome by playing video games or by a frequently ringing mobile phone. | 2003 Jun |
|
The antiallergic drug oxatomide promotes human eosinophil apoptosis and suppresses IL-5-induced eosinophil survival. | 2003 Mar |
|
Evaluation of the effects of anti-pruritic drugs on scratch responses using histamine H1 receptor-deficient mice. | 2003 May 30 |
|
Dietary intake of the flower extracts of German chamomile (Matricaria recutita L.) inhibited compound 48/80-induced itch-scratch responses in mice. | 2003 Nov |
|
[Development of nasal dosage form of oxatomide for rhinitis]. | 2003 Oct |
|
Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. | 2003 Oct |
|
West syndrome associated with administration of a histamine H1 antagonist, oxatomide. | 2004 |
|
Cetirizine: a review of its use in allergic disorders. | 2004 |
|
Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. | 2004 May |
|
The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. | 2004 Nov 22 |
|
Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). | 2005 Aug |
|
Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. | 2005 Feb |
|
Antipruritic effect of the single oral administration of German chamomile flower extract and its combined effect with antiallergic agents in ddY mice. | 2005 Oct 3 |
|
Nimesulide-induced fixed drug eruption. | 2005 Sep-Oct |
|
Solvent effect on the charge transfer complex of oxatomide with 2,3-dichloro-5,6-dicyanobenzoquinone. | 2006 Dec |
|
Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines. | 2006 Jul |
|
[Comparison of clinical efficacy and cost-quality of antihistamines in early treatment for Japanese cedar pollinosis]. | 2006 May |
|
Effect of inhibitor of tumor necrosis factor-alpha and oxatomide on immune mediated otitis media. | 2006 Sep |
|
A simple preparation method for mouse eosinophils and their responses to anti-allergic drugs. | 2007 Mar |
|
CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy. | 2007 Nov |
|
Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro. | 2008 |
|
Determination of oxatomide in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. | 2008 Jul |
|
Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. | 2008 May |
|
Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. | 2009 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
An integrative review of systematic reviews related to the management of breathlessness in respiratory illnesses. | 2010 Dec 9 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
Oxatomide should be taken twice daily, after breakfast and after dinner: 30 mg for adults and 0.5 mg/kg for children older tan 1 year.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8753840
The effect of oxatomide on the immunologic release of preformed (histamine and tryptase) and de novo synthesized mediators (leukotriene C4:LTC4 and prostaglandin D2:PGD2) from human basophils and mast cells purified (from 10 to 82%) from human lung parenchyma (HLMC) and skin tissue (HSMC) was studied in vitro. Preincubation (15 min, 37 degrees C) of basophils with oxatomide (10(-7)-10(-5) M) before Der p I antigen or anti-IgE challenge concentration-dependently (10-40%) inhibited the immunologic release of histamine and LTC4. Oxatomide (10(-7)-10(-5) M) also inhibited (10-40%) histamine, tryptase and LTC4 release from HLMC activated by anti-IgE. In addition, oxatomide caused a concentration-dependent inhibition of histamine, tryptase and PGD2 release from HSMC immunologically challenged with a monoclonal antibody against the alpha chain of the high affinity receptor for IgE (anti-Fc epsilon RI) or anti-IgE.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR06AE06
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
||
|
WHO-ATC |
R06AE06
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12877
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
DTXSID4045181
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
C015408
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
Oxatomide
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
J31IL9Z2EE
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
4329
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
54236
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | RxNorm | ||
|
262-320-9
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
m8294
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | Merck Index | ||
|
60607-34-3
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
SUB09504MIG
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
309710
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
CHEMBL13828
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
4615
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
100000083033
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
C73051
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY | |||
|
2014
Created by
admin on Fri Dec 15 15:23:43 UTC 2023 , Edited by admin on Fri Dec 15 15:23:43 UTC 2023
|
PRIMARY |
ACTIVE MOIETY